Answer
CARVYKTI (ciltacabtagene autoleucel) is contraindicated in patients with hypersensitivity to its active substance or any excipient listed in section 6.1 of its Summary of Product Characteristics.
Sources for this answer
- CARVYKTI 3.2 × 10^6 – 1 × 10^8 cells dispersion for infusionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.3 Contraindications · Version 6Document updated
Sources checked